"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA Approved dabrafenib (Tafinlar; Novartis) and trametinib (Mekinist) for treatment of Melanoma with BRAF V600E or V600K mutations

FDA Approved dabrafenib (Tafinlar; Novartis) and trametinib (Mekinist) for treatment of Melanoma with BRAF V600E or V600K mutations

29 Jun 2018 8:23 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted regular approval to dabrafenib (Tafinlar; Novartis) and trametinib (Mekinist; Novartis) in combination for the adjuvant treatment of patients with melanoma with BRAF 600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. Read full press release. 

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software